To redirect T cells against tumor cells, T cells can be engineered ex vivo to express cancer-
antigen specific T cell receptors (TCRs), generating products known as TCR-engineered T …

Cancer vaccines, which are designed to amplify tumour-specific T cell responses through
active immunization, have long been envisioned as a key tool of effective cancer …

We undertook a comprehensive proteogenomic characterization of 95 prospectively
collected endometrial carcinomas, comprising 83 endometrioid and 12 serous tumors. This …

The remarkable success of immune checkpoint inhibitors demonstrates the potential of
tumour-specific CD8+ T cells to prevent and treat cancer. Although the number of lives …

Lymphoid organs, in which antigen presenting cells (APCs) are in close proximity to T cells,
are the ideal microenvironment for efficient priming and amplification of T-cell responses …

There is abundant evidence that tumor-infiltrating CD8+ T cells contribute positively to
antitumor immunity; however, the role of tumor-infiltrating B cells (TIL-B) and plasma cells …

NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-
testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit …

Cancer immune evasion is a major stumbling block in designing effective anticancer
therapeutic strategies. Although considerable progress has been made in understanding …

Immunotherapies play critical roles in cancer treatment. However, given that only a few
patients respond to immune checkpoint blockades and other immunotherapeutic strategies …

Purpose: Although adoptive cell therapy can be highly effective for the treatment of patients
with melanoma, the application of this approach to the treatment of other solid tumors has …